Clinical trials: Chemotherapy, Adjuvant
Breast Cancer, Chemotherapy Effect
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
According to the latest data from the World Health Organization's International Agency for Research on Cancer (IARC) for 2020, breast cancer has been the most prevalent cancer with 2.26 million new cases.
- Trial name
- NCT05212454
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Cancer
Chemotherapy and Radiation Following Pancreatic Surgery
To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine.
- Trial name
- NCT00660270
- Testing
- Pancreatic Surgery, Radiation therapy, Cisplatin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Washington University School of Medicine
Cervical Cancer
Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
If no metastases are observed, patients will start a short protocol of four courses of weekly neo-adjuvant chemotherapy (12 weeks).
- Trial name
- NEOCON-F (NCT03852979)
- Testing
- Paclitaxel, Carboplatin, conisation
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- The Netherlands Cancer Institute
Colonic Adenocarcinoma
Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over
Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more.
- Trial name
- ADAGE (NCT02355379)
- Testing
- LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation
- Where
- 140 sites in France
- Volunteers
- 774 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Breast Cancer
Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients
The purpose of this study is to assess efficacy of gonadotropin-releasing hormone agonist (goserelin) on the preservation of ovarian reserve function in young breast cancer patients treated with (neo)adjuvant chemotherapy by…
- Trial name
- NCT02430103
- Testing
- Goserelin 3.6 MG
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Peking University People's Hospital
Leiomyosarcoma Uterus
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Addition of postoperative chemotherapy to prevent or delay recurrence in patients newly diagnosed with localized uterine leiomyosarcoma and who have undergone complete tumor surgery.
- Trial name
- L-UteCIN (NCT06524583)
- Testing
- Doxorubicin, Trabectedin
- Where
- 25 sites in France
- Volunteers
- 198 people
- Sponsor
- UNICANCER
Breast Cancer
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
- Trial name
- NCT04136782
- Testing
- Albumin-bound paclitaxel combined with carboplatin, Epirubicin combined with docetaxel
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Breast Cancer
An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy
The aim of this study is to evaluate benefits of the app in breast cancer patients receiving the docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
- Trial name
- NCT05258461
- Testing
- use of a smartphone app for adverse event management, conventional adverse event management
- Volunteers
- 108 people
- Sponsor
- Peking Union Medical College Hospital
Colon Cancer
The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as…
- Trial name
- NCT01991080
- Testing
- biofeedback, Wheatgerm juice
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally…
- Trial name
- NCT04832854
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer Female
Effects of Moderate and High-intensity Exercise During Chemotherapy on Muscle Cells in Women With Breast Cancer
(Neo-)adjuvant chemotherapy for breast cancer has deleterious effects on muscle tissue resulting in reduced skeletal muscle mass, muscle function, and cardiorespiratory fitness.
- Trial name
- PhysCan (NCT05218876)
- Testing
- Low- to moderate intensity strength and endurance training, High intensity strength and endurance training
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Norwegian School of Sport Sciences
Circulating Tumor DNA, Recurrence
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy.
- Conditions
- Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
- Trial name
- CrEATE (NCT06434896)
- Testing
- ctDNA analysis after surgery
- Where
- 29 sites in Netherlands
- Volunteers
- 1,320 people
- Sponsor
- UMC Utrecht
Breast Cancer
Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
This randomized clinical trial compares two systemic treatments for HER2-positive breast cancer. The treatments are given either prior to breast surgery (as neoadjuvant treatment) or after breast surgery (as adjuvant treatment).
- Trial name
- BOLD-1 (NCT02625441)
- Testing
- Pertuzumab, Trastuzumab
- Where
- Finland
- Volunteers
- 516 people
- Sponsor
- Helsinki University Central Hospital
Completely Resected NSCLC With Common EGFR Mutations
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.
This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR mutations.
- Trial name
- NCT03381066
- Testing
- gefitinib, pemetrexed,cisplatin, Vinorelbine, cisplatin
- Where
- South Korea
- Volunteers
- 225 people
- Sponsor
- Yonsei University
Breast Cancer
Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- 12-93 (NCT00002529)
- Testing
- cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 20 sites in Australia, Italy and 5 more
- Volunteers
- 452 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Select 600 cases of women with breast cancer of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis. All the patients were accepted the chemotherapy of Anthracycline and/or Taxane.
- Trial name
- NCT01662128
- Testing
- Xeloda
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer
Background: Taxane plays a key role in the treatment of breast cancer and taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect leading to treatment discontinuation.
- Trial name
- NCT02468739
- Testing
- Ganglioside-monosialic acid
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens
Primary objective: To assess the effect of xaliproden hydrochloride (xaliproden) 1 mg per oral daily on the rate of complete resolution of peripheral sensory neuropathy (PSN) at 6 months, following randomization, after the…
- Trial name
- XENON (NCT00603577)
- Testing
- Xaliproden
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 102 people
- Sponsor
- Sanofi
Head and Neck Cancer
TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer
The purpose of this trial is to compare two different treatments for fit patients with head and neck cancer: All patients are given induction-chemotherapy (docetaxel, cisplatin, 5-FU).
- Trial name
- Condor (NCT00774319)
- Testing
- conventional radiotherapy with 'high' dose cisplatin, accelerated radiotherapy with 'low' dose cisplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Unspecified Adult Solid Tumor, Protocol Specific, Vascular Access Device Complications
Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy
RATIONALE: Giving chemotherapy drugs through an implanted port reduces the need for multiple needle sticks. It is not yet known whether one type of port is more effective than another in reducing infections and other side effects…
- Trial name
- NCT00607880
- Testing
- vascular access device placement
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic